Watson commences shipment of generic Exelon
Posted in Medical Condition on June 30th, 2010Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that, junior to a settling with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis Universal Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic type of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is hardened to scrutinize dementia (a genius disorganize that Read the rest of this entry »
